CeriBell (NASDAQ:CBLL) Director Sells $277,644.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Taylor sold 10,200 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $27.22, for a total value of $277,644.00. Following the completion of the sale, the director directly owned 38,278 shares in the company, valued at $1,041,927.16. This trade represents a 21.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, August 13th, Joseph Taylor sold 13,095 shares of CeriBell stock. The shares were sold at an average price of $23.40, for a total value of $306,423.00.

CeriBell Stock Down 5.2%

Shares of NASDAQ CBLL opened at $26.35 on Friday. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -13.58 and a beta of 0.86. CeriBell, Inc. has a 12 month low of $12.36 and a 12 month high of $28.89. The stock has a 50-day moving average price of $25.49 and a two-hundred day moving average price of $21.02.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. As a group, analysts forecast that CeriBell, Inc. will post -2.05 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

Hedge funds have recently made changes to their positions in the company. Sei Investments Co. grew its holdings in shares of CeriBell by 2.3% during the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the last quarter. Strs Ohio acquired a new position in shares of CeriBell in the first quarter valued at approximately $27,000. Legal & General Group Plc bought a new position in CeriBell in the 2nd quarter valued at approximately $53,000. State of Wyoming bought a new position in CeriBell in the 1st quarter valued at approximately $62,000. Finally, Quantinno Capital Management LP boosted its position in CeriBell by 3.0% during the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock worth $2,573,000 after buying an additional 4,119 shares during the period.

Wall Street Analyst Weigh In

Several brokerages recently commented on CBLL. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group boosted their target price on shares of CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Finally, TD Cowen increased their price target on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.25.

CeriBell Company Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.